Description  Claims  Drawing  Cited references 

WO2008085828A   [0011]  [0012] 
WO2007033215A   [0011] 
US27204211   [0024] 
WO2010132879A   [0024] 
WO11847661A   [0120] 
WO61421706A   [0120] 
WO61546314A   [0120] 

Pharmaceutical Salts   [0023] 
Computer Applic. Biol. Sci.   [0033] 
Remington: The Science and Practice of Pharmacy   [0056]  [0057]  [0058] 
Synthesis of the next generation therapeutic antibodies that combine cell targeting and antibody-catalyzed prodrug activation   [0118] 
The endothelial cell tube formation assay on basement membrane turns 20: state of the science and the art   [0118] 
Integrins in angiogenesis and lymphangiogenesis   [0118] 
Vascular differences detected by MRI for metastatic versus nonmetastatic breast and prostate cancer xenografts   [0118] 
Targeting tumors with peptides from natural sources   [0118] 
Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium   [0118] 
Angiogenesis in life, disease and medicine   [0118] 
Angiogenesis in cancer and other diseases   [0118] 
Molecular mechanisms and clinical applications of angiogenesis   [0118] 
Identification of amino acids essential for the antiangiogenic activity of tumstatin and its use in combination antitumor activity   [0118] 
Tail vein assay of cancer metastasis   [0118] 
Tumor angiogenesis: therapeutic implications   [0118] 
Role of angiogenesis in tumor growth and metastasis   [0118] 
Angiogenesis   [0118] 
Biochemical and structural analysis of the binding determinants of a vascular endothelial growth factor receptor peptidic antagonist   [0118] 
Chemical modifications designed to improve peptide stability: incorporation of non-natural amino acids, pseudo-peptide bonds, and cyclization   [0118] 
Thrombospondin-1 mimetic peptide inhibitors of angiogenesis and tumor growth: design, synthesis, and optimization of pharmacokinetics and biological activities   [0118] 
Perspectives on lymphangiogenesis and angiogenesis in cancer   [0118] 
Design, synthesis, and conformation of superpotent and prolonged acting melanotropins   [0118] 
Identification of novel short peptides derived from the alpha 4, alpha 5, and alpha 6 fibrils of type IV collagen with anti-angiogenic properties   [0118] 
A systematic methodology for proteome-wide identification of peptides inhibiting the proliferation and migration of endothelial cells   [0118] 
Phase I trial of the positron-emitting Arg-Gly-Asp (RGD) peptide radioligand 18F-AH111585 in breast cancer patients   [0118] 
Peptides derived from type IV collagen, CXC chemokines, and thrombospondin-1 domain-containing proteins inhibit neovascularization and suppress tumor growth in MDA-MB-231 breast cancer xenografts   [0118] 
Pentastatin-1, a collagen IV derived 20-mer peptide, suppresses tumor growth in a small cell lung cancer xenograft model   [0118] 
Small peptides derived from somatotropin conserved domain-containing proteins inhibit blood and lymphatic endothelial cell proliferation, migration, adhesion and tube formation   [0118] 
Vascular endothelial growth factor is a secreted angiogenic mitogen   [0118] 
Structure-activity relationship studies of permeability modulating peptide AT-1002   [0118] 
Unnatural amino acids in drug discovery   [0118] 
Short pigment epithelial-derived factor-derived peptide inhibits angiogenesis and tumor growth   [0118] 
A phase 1 trial of ABT-510 concurrent with standard chemoradiation for patients with newly diagnosed glioblastoma   [0118] 
Albumin labeled with Gd-DTPA. An intravascular contrast-enhancing agent for magnetic resonance blood pool imaging: preparation and characterization   [0118] 
Transgenic mice with increased expression of vascular endothelial growth factor in the retina: a new model of intraretinal and subretinal neovascularization   [0118] 
Stability of peptides and therapeutic success in cancer   [0118] 
Characterizing vascular parameters in hypoxic regions: A combined magnetic resonance and optical imaging study of a human prostate cancer model   [0118] 
Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme   [0118] 
Development trends for peptide therapeutics   [0118] 
Novel peptide specific QSAR analysis applied to collagen IV peptides with antiangiogenic activity   [0118] 
Anti-angiogenic peptides for cancer therapeutics   [0118] 
Development of a biomimetic peptide derived from collagen IV with anti-angiogenic activity in breast cancer   [0118] 
Current trends in the clinical development of peptide therapeutics   [0118] 
Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid   [0118] 
Campochiaro PA: Evolution of neovascularization in mice with overexpression of vascular endothelial growth factor in photoreceptors   [0118]